Skip to navigation Skip to content

Neuromyelitis optica spectrum disorder (NMOSD) in Pharmaceutical Benefits Scheme (PBS) 012-25030536

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ravulizumab for patients with neuromyelitis optica spectrum disorder (NMOSD).

NMOSD and listing dates

NMOSD is a rare spectrum of autoimmune conditions where the optic (eye) nerve, spinal cord and brain is damaged by inflammation.

Listing date: ravulizumab - 1 April 2025

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition being treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • FAQs from Service Officers
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs